KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EBT (2019 - 2025)

Historic EBT for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $6.1 million.

  • GoodRx Holdings' EBT fell 2480.28% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.8 million, marking a year-over-year increase of 127264.4%. This contributed to the annual value of $31.5 million for FY2024, which is 15661.12% up from last year.
  • GoodRx Holdings' EBT amounted to $6.1 million in Q3 2025, which was down 2480.28% from $19.6 million recorded in Q2 2025.
  • GoodRx Holdings' 5-year EBT high stood at $19.6 million for Q2 2025, and its period low was -$46.6 million during Q3 2023.
  • Moreover, its 5-year median value for EBT was $3.6 million (2023), whereas its average is -$798684.2.
  • In the last 5 years, GoodRx Holdings' EBT plummeted by 215452.03% in 2022 and then skyrocketed by 558873.72% in 2025.
  • GoodRx Holdings' EBT (Quarter) stood at $5.9 million in 2021, then crashed by 180.83% to -$4.7 million in 2022, then plummeted by 419.18% to -$24.6 million in 2023, then skyrocketed by 146.31% to $11.4 million in 2024, then crashed by 46.53% to $6.1 million in 2025.
  • Its last three reported values are $6.1 million in Q3 2025, $19.6 million for Q2 2025, and $16.7 million during Q1 2025.